Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
03-06 November, 2024
2024 ACI Convention2024 ACI Convention
Not Confirmed
Not Confirmed
03-07 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
03-06 November, 2024
2024 ACI Convention2024 ACI Convention
Industry Trade Show
Not Confirmed
03-07 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/due-to-its-20-year-mastery-in-micronization-inke-has-emerged-a-cornerstone-in-treating-global-respiratory-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
12 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announced-that-the-phase-3-pathway-china-trial-of-palopegteriparatide-achieved-primary-and-key-secondary-endpoints-in-the-treatment-of-adults-with-hypoparathyroidism-302219715.html
07 Mar 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/visen-announces-acceptance-of-a-biologics-license-application-for-lonapegsomatropin-in-china-302082740.html
06 Jan 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/double-blind-period-completes-primary-endpoint-analysis-of-phase-3-clinical-trial-to-be-conducted-for-chinas-first-hormone-replacement-treatment-targeting-hypoparathyroidism-301715285.html
17 Nov 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/visen-discloses-52-week-clinical-results-for-its-china-phase-3-trial-of-lonapegsomatropin-301681121.html
23 May 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/05/23/2448375/0/en/Positive-Results-from-VISEN-s-Phase-3-Trial-of-Once-Weekly-TransCon-hGH-in-China-Consistent-with-Ascendis-Pharma-s-Phase-3-Height-Trial.html
23 May 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/visen-pharmaceuticals-announces-top-line-results-of-phase-3-trial-of-once-weekly-lonapegsomatropin-demonstrating-superior-efficacy-comparable-safety-and-tolerability-to-daily-growth-hormone-301552704.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?